Table 1. Validated associations between copy number amplifications and clinical outcomes.
| Clinical outcome | CNA-harboring gene | Hazard ratio | P value |
|---|---|---|---|
| Local recurrence | PIK3CA | 2.332341 | 0.006 |
| Distant metastases | FGFR1 | 3.043851 | 0.001 |
| Distant metastases | SMO | 8.034381 | 0.003 |
| Distant metastases | RB1 | 9.043599 | 0.002 |
| Distant metastases | RET | 13.32504 | 0.011 |
| Disease-free survival | PIK3CA | 1.987948 | 0.0008 |
| Disease-free survival | ATM | 14.10226 | 0.009 |
| Disease-free survival | STK11 | 31.09854 | 0.0009 |
| Disease-free survival | RET | 14.37666 | 0.009 |
| Disease-specific survival | PIK3CA | 1.945889 | 0.002 |
| Disease-specific survival | ATM | 12.80487 | 0.012 |
| Disease-specific survival | STK11 | 31.24429 | 0.0009 |
| Overall survival | PIK3CA | 1.69732 | 0.007 |
| Overall survival | ATM | 11.89914 | 0.015 |
| Overall survival | CDH1 | 3.323677 | 0.008 |
| Overall survival | STK11 | 27.2731 | 0.001 |